News > Venus Remedies launches its flagship R&D drug Elores in Oman

Venus Remedies launches its flagship R&D drug Elores in Oman

Venus Remedies Ltd, a leading research-driven pharmaceutical company, has launched its flagship R&D drug, Elores, in the $1.4-billion pharmaceutical market in Oman. Venus Remedies is targeting the $237-million antibiotic market in GCC region, out of which 35 per cent accounts for ESBL and MBL resistance segment, to which Elores caters; the company aims to secure a 0.1 per cent share in this segment, which amounts to $0.235 million.